
    
      This is a randomized, double-blind, controlled trial in which patients with long-standing
      clinically inactive UC receiving ASA for maintenance of remission will be randomized to
      either continue 5-ASA or to receive an equivalent placebo for 12 months. The primary endpoint
      is clinical relapse at 12 months.
    
  